ARTICLE | Clinical News

Abiraterone extends overall survival in CRPC

October 12, 2010 12:53 AM UTC

Johnson & Johnson (NYSE:JNJ) said once-daily abiraterone plus twice-daily predinose/prednisolone significantly improved overall survival by 36% vs. placebo plus prednisone/prednisolone in the Phase III COU-AA-301 trial to treat metastatic castration-resistant prostate cancer (14.8 vs. 10.9 months). Last month, J&J unblinded the COU-AA-301 trial at the recommendation of an independent DMC after a pre-specified interim analysis showed that abiraterone met the primary endpoint of OS and had an acceptable safety profile.

The double-blind, international trial enrolled 1,195 patients with CRPC previously treated with one or two chemotherapy regimens, at least one of which contained Taxotere docetaxel. Data were presented at the European Society for Medical Oncology meeting in Milan. Abiraterone is an inhibitor of steroidal enzyme 17 alpha-hydroxylase/C17, 20 lyase ( CYP17). ...